Workshop on biosimilar medicines to be hosted by European Commission

On the 5th May 2017, the European Commission is hosting a multi-stakeholder workshop to develop a Q&A on the use of biosimilar medicines aimed at healthcare professionals. The session follows two previous workshops, where information has been gathered and subsequently shared to enhance patient understanding and trust of the use of biosimilars throughout Europe. The European Commission Q&A on biosimilar medicines which was published at the end of January 2017, was drafted alongside the European Medicines Agency (EMA) and other relevant stakeholders; the European Patients Forum (EPF), the European Federation of Crohns a& Ulcerative Colitis Associations (EFCCA), the Standing Committee of European Doctors, European Federation of Pharmaceutical Industries and Associations (EPFIA), European Association of Bio-industries (EuropaBio) and Medicines for Europe. At PharmaLex we have considerable expertise in the development of biosimilars. If you are developing biosimilars for the EU or US and would like to discuss your requirements, please contact us on uk@pharmalex.com or call +44 (0)1628 530554.

For more information on Workshop on biosimilar medicines to be hosted by European Commission talk to PharmaLex UK Services Limited